On December 3, 2024, Novavax CZ, a subsidiary of Novavax Inc., entered into an asset purchase agreement with Novo Nordisk Production Czech and Novo Nordisk A/S. The agreement involves the sale of Novavax's biologics manufacturing campus in Bohumil, Czech Republic, for $200 million.The transaction includes the transfer of properties, movable assets, equipment, contracts, and certain employees. An initial payment of $10 million was made in September 2024, with an additional $10 million placed in escrow for release 12 months post-closing.The deal's closure is contingent upon regulatory approval from the Czech State Institute for Drug Control. The agreement allows for termination if conditions are unmet by April 2025, with Novo Nordisk covering operational costs up to $3.5 million monthly until closing.

On December 3, 2024, Novavax CZ, a subsidiary of Novavax Inc., entered into an asset purchase agreement with Novo Nordisk Production Czech and Novo Nordisk A/S. The agreement involves the sale of Novavax's biologics manufacturing campus in Bohumil, Czech Republic, for $200 million.The transaction includes the transfer of properties, movable assets, equipment, contracts, and certain employees. An initial payment of $10 million was made in September 2024, with an additional $10 million placed in escrow for release 12 months post-closing.The deal's closure is contingent upon regulatory approval from the Czech State Institute for Drug Control. The agreement allows for termination if conditions are unmet by April 2025, with Novo Nordisk covering operational costs up to $3.5 million monthly until closing.